February 10, 2026 4:52pm

Indexes shaved its “spoils”; present and coming econs and earnings contaminated sector advances 

Indexes are coming off a 2nd straight day of gains as tech stocks rallied, building on their Friday comeback. The Dow in particular notched fresh highs on an intraday and closing basis. Investors are hopeful the market can sustain its upward advance after last week’s sell-off failed to meaningfully hurt the market on a technical basis. <CNBC>

Always be ready for an alternate view!

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

Tuesday’s RMi Pre-opening: After new record highs … https://www.regmedinvestors.com/articles/14306

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Tuesday: The Dow closed UP +52.27 points or +0.10%, the S&P closed DOWN -23.02 points or -0.33% while the Nasdaq closed DOWN -136.196 points or -0.59%

  • Theme of the session: under pressure awaiting CPI on Friday

Tuesday’s (my) 40-company covered sector’s advance/decline line opened positive with 22 incliners, 16 decliners and 2 flats, ending with a barely negative close of 19 incliners, 20 decliners and 1 flat

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • Consumer spending in December was flat, missing the 0.4% monthly gain that economists were expecting. Retail sales had increased 0.6% in November.

The CBOE Fear (VIX) index, Tuesday closed at 17.23, after Monday’s 17.44, Friday’s 17.75, Thursday’s 21.63, Wednesday’s 19.25 and last Tuesday’s 17.91

Metrics: Tuesday …

  • The RUT was up +13.46 points or +0.50%,
  • The XLV was down -0.17 points or -0.11%,
  • The NBI was down -213.73 points or -0.40%;
  • The XBI was up +0.26 points or +0.21%
  • The IWM was up +0.92 or +0.34%;
  • The IBB was down -0.76 points or -0.44%,
  • The VIX was down -0.13 points or -0.75% at to 17.23

 

Q1/26 February – 4 negative and 3 positive sessions

  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Tuesday Closing UP (10 of 19) 

  • Alnylam Pharmaceuticals (ALNY +$2.98 after Monday’s -$8.16),
  • Mesoblast (MESO +$1.;21 after Monday’s +$0.83),
  • AxoGen (AXGN +$0.58 after Monday’s -$1.00),
  • Arrowhead Pharmaceuticals (ARWR +$0.32 after Monday’s -$1.88),
  • Entrada Therapeutics (TRDA +$0.28),
  • Cellectis SA (CLLS +$0.27),
  • Vericel (VCEL +$0.15 after Monday’s -$0.75),
  • Dyne therapeutics (DYN +$0.15),
  • Harvard Apparatus RT (OTCQB: HRGN +$0.10 <with 660 shares> after Monday’s $0.00),
  • Precigen (PGEN +$0.10),

Flat (1)

  • Generation Bio (GBIO) - acquired

Tuesday’s Closing DOWN (10 of 20): 

  • IQIA Holdings (IQV -$10.22 after Monday’s +$5.27),
  • Vertex (VRTX -$7.39 after Monday’s -$7.05),
  • Regenxbio (RGNX -$1.46),
  • BioNTech (BNTX -$1.41 after Monday’s +$3.72),
  • uniQure NV (QURE -$1.34 after Monday’s +$0.40),
  • CRISPR Therapeutics (CRSP -$0.87 after Monday’s +$0.96),
  • Intellia Therapeutics (NTLA -$0.58),
  • Capricor Therapeutics (CAPR -$0.56 after Monday’s +$0.47),
  • Ionis Pharmaceuticals (IONS -$0.50 after Monday’s -$1.71),
  • Lenz Therapeutics (LENZ -$0.35 after Monday’s -$0.21),

 

The Bottom Line: More of the … WHY

Indexes were mixed as the Dow stayed up … after weaker-than-expected retail sales data.

  • The consumer data lays the ground for Wednesday's all-important January jobs report, in high focus following last week's signs of softening in the labor market.
  • The latest Consumer Price Index reading is then due on Friday to give a look at inflation pressures, as the Fed continues to balance both sides of its dual mandate. <Yahoo Finance>

Earnings release dates:

  • 2/12 – Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Ultragenyx Pharmaceuticals (RARE)
  • 2/13 – Moderna (MRNA)

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

February – 2nd week

  • 2/10 - Tuesday closed negative with 19 incliners, 20 decliners and 1 flat
  • 2/9 -Monday closed positive with 23 incliners, 14 decliners and 3 flats

February – 1st week

  • 2/6 – Friday closed positive with 35 incliners, 5 decliners and 0 flat
  • 2/5 -Thursday closed negative with 2 incliners, 36 decliners and 2 flats
  • 2/4 -Wednesday closed negative with 10 incliners, 29 decliners and 1 flat               
  • 2/3 -Tuesday closed negative with 18 incliners, 21 decliners and 1 flat      
  • 2/2 -Monday closed positive with 29 incliners, 10 decliners and 1 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Tuesday: Alnylam Pharmaceuticals (ALNY), Mesoblast (MESO) and AxoGen (AXGN)
  • Monday: IQIA Holdings (IQV), BioNTech (BNTX) and Mesoblast (MESO)
  • Friday: Vertex (VRTX), IQIA Holdings (IQV) and Ionis Pharmaceuticals (IONS)

The worst three (3) in the session: Losers

  • Tuesday: : IQIA Holdings (IQV), Vertex (VRTX) and Regenxbio (RGNX)
  • Monday: BioNTech (BNTX), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR)
  • Friday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and Generation Bio (GBIO)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.